Rheumatoid Arthritis Awareness Day: Feb 2

Article contributed by Prarthana Jain, DO MPH

A Reflection on Early Disease, Precision Therapy and Unmet Needs

Rheumatoid Arthritis (RA) Awareness Day offers an opportunity not only to educate patients and the public, but also to reflect as rheumatology providers on how far the field has advanced and where gaps in care persist. Despite increasing diagnostics and therapeutics, RA remains a disease in which delays in recognition, undertreatment and inequities in access continue to drive preventable morbidity.

RA Is Still Diagnosed Too Late

Although classification criteria and imaging tools have improved, many patients continue to experience delays in diagnosis. Seronegative disease, intermittent symptoms and early complaints being attributed to mechanical or degenerative causes remain common contributors.

Musculoskeletal ultrasounds have increasingly become an adjunct to the physical exam, particularly in early or borderline disease. Power Doppler-positive synovitis can reveal clinically meaningful inflammation even when swelling is not present on exam. As a specialty, maintaining a strong focus on early diagnosis and timely access to rheumatology care remains essential.

Beyond Serologies

RA is increasingly understood as a heterogeneous disease rather than a single clinical entity. Autoantibody status, extra-articular manifestations, smoking history, along with genetic and environmental factors influence prognosis and therapeutic response.

Seronegative RA continues to pose diagnostic and management challenges, often requiring greater reliance on imaging, longitudinal symptom assessment and response to therapy. In contrast, seropositive RA should prompt early conversations about long-term risk, erosive disease and systemic involvement.

Successes and Real-World Barriers

Though treat-to-target paradigm has clearly improved outcomes in RA, real-world implementation remains inconsistent. Provider time constraints, patient uncertainty, medication access and insurance-driven step therapy often interfere with timely escalation of care.

At the same time, the growing number of conventional DMARDs, biologics and targeted synthetic agents have made treatment more individualized, but also more complex. Shared decision-making now routinely includes discussions about infection risk, comorbidities, malignancy signals, reproductive planning and lifestyle factors. Balancing these factors while maintaining momentum toward remission remains a daily clinical challenge.

Extra-Articular Disease

RA remains a systemic inflammatory disease with implications well beyond synovitis. Interstitial lung disease, accelerated atherosclerosis, osteoporosis and fatigue significantly contribute to morbidity and mortality. These complications often evolve silently and may be under-recognized in routine follow-up.

RA Awareness Day serves as a reminder to continue to monitor for extra-articular manifestations and to routinely incorporate preventive care, including vaccinations, bone health and cardiovascular risk reduction into RA management.

Looking Forward

The future of RA care lies in earlier diagnosis, better disease stratification and precision medicine. Biomarkers predicting treatment response, wider integration of imaging into routine care and novel pathways targeting residual inflammation may further close the gap between clinical remission and true disease control.

At the North Carolina Rheumatology Association, we recognize not only the burden our patients carry, but also our responsibility as providers to continue refining how RA is diagnosed, treated and monitored. Progress in RA has been one of rheumatology’s greatest success stories, but the work is far from finished.